Free Trial

BridgeBio Pharma (BBIO) Financials

BridgeBio Pharma logo
$38.19 -0.38 (-0.98%)
As of 11:41 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Annual Income Statements for BridgeBio Pharma

Annual Income Statements for BridgeBio Pharma

This table shows BridgeBio Pharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders
-31 -131 -261 -449 -563 -481 -643 -536
Consolidated Net Income / (Loss)
-44 -169 -289 -505 -586 -485 -653 -543
Net Income / (Loss) Continuing Operations
-44 -169 -289 -505 -586 -485 -653 -543
Total Pre-Tax Income
-44 -169 -289 -505 -586 -485 -653 -542
Total Operating Income
-44 -184 -266 -474 -577 -512 -607 -593
Total Gross Profit
0.00 0.00 41 8.25 67 74 6.86 218
Total Revenue
0.00 0.00 41 8.25 70 78 9.30 222
Operating Revenue
0.00 0.00 41 8.25 70 78 9.30 222
Total Cost of Revenue
0.00 0.00 0.00 0.00 3.11 3.43 2.45 3.88
Operating Cost of Revenue
- - 0.00 - 3.11 3.43 2.45 3.88
Total Operating Expenses
44 184 307 483 643 586 614 811
Selling, General & Admin Expense
13 44 94 146 192 143 151 289
Research & Development Expense
31 140 210 337 451 399 456 506
Restructuring Charge
- - - 0.00 0.00 44 7.93 16
Total Other Income / (Expense), net
0.03 14 -22 -31 -9.82 28 -46 51
Interest Expense
0.01 2.55 8.77 37 47 80 81 126
Interest & Investment Income
0.04 21 -12 4.02 1.13 7.54 18 164
Other Income / (Expense), net
0.00 -4.30 -1.63 1.63 36 100 17 12
Income Tax Expense
- - - - - 0.00 0.00 1.15
Net Income / (Loss) Attributable to Noncontrolling Interest
-13 -39 -28 -57 -24 -3.47 -10 -7.59
Basic Earnings per Share
($1.00) ($2.12) ($2.48) ($3.80) ($3.90) ($3.26) ($3.95) ($2.88)
Weighted Average Basic Shares Outstanding
30.60M 61.77M 105.10M 118.00M 144.36M 147.47M 162.79M 186.08M
Diluted Earnings per Share
($1.00) ($2.12) ($2.48) ($3.80) ($3.90) ($3.26) ($3.95) ($2.88)
Weighted Average Diluted Shares Outstanding
30.60M 61.77M 105.10M 118.00M 144.36M 147.47M 162.79M 186.08M
Weighted Average Basic & Diluted Shares Outstanding
30.60M 61.77M 105.10M 118.00M 144.36M 151.37M 175.83M 190.19M

Quarterly Income Statements for BridgeBio Pharma

This table shows BridgeBio Pharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-137 -138 -140 -158 -177 -168 -35 -73 -162 -265 -167
Consolidated Net Income / (Loss)
-140 -141 -143 -161 -179 -170 -36 -76 -164 -267 -170
Net Income / (Loss) Continuing Operations
-140 -141 -143 -161 -179 -170 -36 -76 -164 -267 -170
Total Pre-Tax Income
-140 -141 -143 -161 -179 -170 -36 -76 -164 -266 -170
Total Operating Income
-129 -129 -126 -146 -158 -177 0.34 -176 -192 -226 -104
Total Gross Profit
-0.40 -0.13 1.18 1.04 3.49 1.15 211 1.57 2.13 3.80 114
Total Revenue
0.34 1.87 1.83 1.64 4.09 1.75 211 2.17 2.73 5.88 117
Operating Revenue
0.34 1.87 1.83 1.64 4.09 1.75 211 2.17 2.73 5.88 117
Total Cost of Revenue
0.74 2.00 0.65 0.60 0.60 0.60 0.60 0.60 0.60 2.08 2.64
Operating Cost of Revenue
0.74 - 0.65 0.60 0.60 0.60 0.60 0.60 0.60 2.08 2.64
Total Operating Expenses
129 130 127 147 161 179 210 177 194 230 218
Selling, General & Admin Expense
31 32 31 36 36 48 66 60 69 95 106
Research & Development Expense
93 91 93 107 125 130 141 115 120 130 111
Restructuring Charge
5.02 7.69 3.37 3.53 0.27 0.75 3.40 2.89 4.62 4.69 0.57
Total Other Income / (Expense), net
-11 -11 -17 -15 -22 7.09 -37 100 27 -40 -65
Interest Expense
20 20 20 21 20 20 50 23 23 30 63
Interest & Investment Income
2.42 4.09 4.15 4.51 3.79 5.58 4.08 124 49 -12 -10
Other Income / (Expense), net
6.33 4.56 -0.60 1.48 -5.28 22 9.48 -0.63 1.80 1.62 8.23
Net Income / (Loss) Attributable to Noncontrolling Interest
-2.85 -2.98 -2.58 -2.80 -2.49 -2.18 -0.94 -2.09 -2.21 -2.34 -2.19
Basic Earnings per Share
($0.93) ($0.91) ($0.92) ($0.98) ($1.08) ($0.97) ($0.20) ($0.39) ($0.86) ($1.43) ($0.88)
Weighted Average Basic Shares Outstanding
147.94M 147.47M 152.65M 160.54M 163.31M 162.79M 178.71M 187.59M 188.51M 186.08M 190.15M
Diluted Earnings per Share
($0.93) ($0.91) ($0.92) ($0.98) ($1.08) ($0.97) ($0.20) ($0.39) ($0.86) ($1.43) ($0.88)
Weighted Average Diluted Shares Outstanding
147.94M 147.47M 152.65M 160.54M 163.31M 162.79M 178.71M 187.59M 188.51M 186.08M 190.15M
Weighted Average Basic & Diluted Shares Outstanding
149.48M 151.37M 160.50M 162.47M 173.97M 175.83M 187.13M 188.03M 188.99M 190.19M 189.88M

Annual Cash Flow Statements for BridgeBio Pharma

This table details how cash moves in and out of BridgeBio Pharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents
72 344 -72 -5.52 38 21 -22 289
Net Cash From Operating Activities
-40 -137 -254 -400 -498 -419 -528 -521
Net Cash From Continuing Operating Activities
-40 -137 -254 -400 -498 -419 -528 -521
Net Income / (Loss) Continuing Operations
-44 -169 -289 -505 -586 -485 -653 -543
Consolidated Net Income / (Loss)
-44 -169 -289 -505 -586 -485 -653 -543
Depreciation Expense
- - 0.86 1.46 5.84 6.77 6.49 6.08
Non-Cash Adjustments To Reconcile Net Income
2.10 10 45 86 61 30 114 -15
Changes in Operating Assets and Liabilities, net
1.24 22 -11 18 21 28 5.06 32
Net Cash From Investing Activities
-0.46 -21 -217 -53 -201 453 54 61
Net Cash From Continuing Investing Activities
-0.46 -21 -217 -53 -201 453 54 61
Purchase of Property, Plant & Equipment
-0.46 -2.18 -2.64 -7.52 -13 -4.82 -1.31 -0.93
Acquisitions
0.00 -16 0.00 0.00 -35 -1.50 0.00 -7.98
Purchase of Investments
0.00 0.00 -213 -288 -643 -193 -137 -114
Sale of Property, Plant & Equipment
- 0.00 - 0.00 0.00 10 0.00 0.00
Sale and/or Maturity of Investments
- 0.00 0.00 249 477 533 193 184
Other Investing Activities, net
- 0.00 -1.72 -6.76 14 110 -0.50 -0.14
Net Cash From Financing Activities
113 502 399 447 736 -13 452 748
Net Cash From Continuing Financing Activities
113 502 397 447 733 -13 452 748
Repayment of Debt
0.13 55 -0.82 -13 -140 -20 0.00 -489
Issuance of Debt
4.00 1.00 37 550 1,204 0.00 0.00 450
Issuance of Common Equity
0.00 96 391 25 3.82 7.41 453 319
Other Financing Activities, net
2.98 59 25 -35 -49 -0.90 -1.67 469
Cash Interest Paid
0.00 1.57 6.09 15 30 54 61 91

Quarterly Cash Flow Statements for BridgeBio Pharma

This table details how cash moves in and out of BridgeBio Pharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Change in Cash & Equivalents
13 -69 18 -110 199 -129 83 72 -142 275 -141
Net Cash From Operating Activities
-135 -93 -144 -113 -145 -125 -220 75 -181 -195 -199
Net Cash From Continuing Operating Activities
-135 -93 -144 -113 -145 -125 -220 75 -181 -195 -199
Net Income / (Loss) Continuing Operations
-140 -141 -143 -161 -179 -170 -36 -76 -164 -267 -170
Consolidated Net Income / (Loss)
-140 -141 -143 -161 -179 -170 -36 -76 -164 -267 -170
Depreciation Expense
1.65 1.66 1.63 1.64 1.64 1.59 1.60 1.57 1.54 1.37 1.28
Non-Cash Adjustments To Reconcile Net Income
4.96 40 35 34 35 10 -194 137 -16 56 85
Changes in Operating Assets and Liabilities, net
-1.58 6.10 -38 11 -2.13 34 8.54 12 -2.32 14 -116
Net Cash From Investing Activities
147 18 12 4.12 38 -0.07 23 3.04 38 -3.24 -1.60
Net Cash From Continuing Investing Activities
147 18 12 4.12 38 -0.07 23 3.04 38 -3.24 -1.60
Purchase of Property, Plant & Equipment
-0.76 -0.80 -0.01 -0.43 -0.43 -0.44 -0.70 -0.05 -0.14 -0.05 0.00
Acquisitions
- - 0.00 - - - -0.80 -2.39 -1.60 -3.19 -1.60
Purchase of Investments
-30 -32 -47 -44 -17 -29 -65 -49 - - 0.00
Sale and/or Maturity of Investments
178 51 60 48 55 30 89 55 40 - 0.00
Net Cash From Financing Activities
1.45 6.38 150 -1.23 307 -4.52 280 -5.73 0.71 474 60
Net Cash From Continuing Financing Activities
1.45 6.38 150 -1.23 307 -4.52 280 -5.73 0.71 474 60
Repayment of Debt
- 1.96 5.74 -1.18 -4.56 - -486 -3.73 - - -471
Repurchase of Common Equity
- - - - - - - - - - -48
Issuance of Debt
- - 0.00 - - - 450 - - - 575
Issuance of Common Equity
1.59 4.85 145 1.03 308 -0.45 318 -0.50 2.12 - 3.24
Other Financing Activities, net
-0.15 -0.43 -0.32 -1.08 3.80 -4.07 -2.40 -1.50 -1.41 474 1.55
Cash Interest Paid
22 6.87 22 6.68 22 10 35 14 29 13 23

Annual Balance Sheets for BridgeBio Pharma

This table presents BridgeBio Pharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets
465 632 704 1,013 623 546 919
Total Current Assets
445 569 643 889 549 478 721
Cash & Equivalents
436 364 356 394 377 376 681
Restricted Cash
- - - 0.18 38 17 0.13
Short-Term Investments
0.00 182 251 443 95 59 0.00
Note & Lease Receivable
- - - 20 17 0.00 0.00
Accounts Receivable
- 2.85 - - - 1.75 4.72
Prepaid Expenses
9.14 20 36 32 22 24 35
Plant, Property, & Equipment, net
1.58 5.63 20 30 15 12 7.01
Total Noncurrent Assets
18 57 40 94 60 57 192
Long-Term Investments
17 31 - - - 0.00 144
Intangible Assets
- - 0.00 45 29 26 24
Other Noncurrent Operating Assets
1.09 26 40 49 31 31 24
Total Liabilities & Shareholders' Equity
465 632 704 1,013 623 546 919
Total Liabilities
88 156 596 1,878 1,868 1,889 2,377
Total Current Liabilities
33 60 96 135 121 144 154
Accounts Payable
14 8.85 8.95 12 12 11 9.62
Accrued Expenses
12 26 46 81 67 66 67
Current Deferred Revenue
- - - 0.00 8.16 6.10 15
Current Employee Benefit Liabilities
4.05 13 30 37 31 57 58
Other Current Liabilities
3.01 12 9.35 4.94 3.68 4.13 4.51
Total Noncurrent Liabilities
55 95 500 1,743 1,747 1,745 2,223
Long-Term Debt
55 92 92 431 431 446 437
Noncurrent Deferred Revenue
- - - - - 3.73 17
Other Noncurrent Operating Liabilities
0.50 3.53 408 1,313 1,316 1,295 1,768
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest
0.12 2.24 1.63 1.42 -1.59 0.48 0.14
Total Equity & Noncontrolling Interests
377 474 106 -867 -1,243 -1,343 -1,458
Total Preferred & Common Equity
315 408 58 -870 -1,255 -1,354 -1,468
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
315 408 58 -870 -1,255 -1,354 -1,468
Common Stock
494 848 1,021 842 939 1,481 1,903
Retained Earnings
-179 -440 -889 -1,437 -1,918 -2,561 -3,096
Treasury Stock
- 0.00 -75 -275 -275 -275 -275
Accumulated Other Comprehensive Income / (Loss)
0.00 0.25 0.19 -0.13 -0.33 0.03 0.01
Noncontrolling Interest
62 65 48 3.41 11 11 10

Quarterly Balance Sheets for BridgeBio Pharma

This table presents BridgeBio Pharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025
Total Assets
729 626 504 655 849 794 665 882
Total Current Assets
642 553 433 588 783 616 445 695
Cash & Equivalents
483 407 302 505 475 408 266 541
Accounts Receivable
- - - - - - - 115
Inventories, net
- - - - - - - 3.95
Prepaid Expenses
26 25 21 23 28 28 38 35
Plant, Property, & Equipment, net
16 14 13 12 11 9.84 8.70 6.70
Total Noncurrent Assets
71 59 58 55 54 168 212 180
Long-Term Investments
- - - - - 117 160 128
Intangible Assets
29 28 28 27 26 25 25 28
Other Noncurrent Operating Assets
42 31 30 28 29 26 27 24
Total Liabilities & Shareholders' Equity
729 626 504 655 849 794 665 882
Total Liabilities
1,859 1,839 1,853 1,849 1,886 1,876 1,883 2,520
Total Current Liabilities
119 97 110 106 141 134 139 152
Accounts Payable
10 4.08 3.87 4.47 4.73 18 13 28
Accrued Expenses
73 63 68 57 86 67 66 34
Current Deferred Revenue
7.52 6.68 6.21 6.59 14 15 12 12
Current Employee Benefit Liabilities
25 19 29 34 32 29 44 33
Other Current Liabilities
4.04 3.67 3.78 4.14 4.54 4.62 4.60 46
Total Noncurrent Liabilities
1,740 1,743 1,743 1,743 1,745 1,742 1,744 2,368
Long-Term Debt
1,699 436 440 442 435 435 436 0.00
Noncurrent Deferred Revenue
- - - - 20 17 19 18
Other Noncurrent Operating Liabilities
41 1,307 1,303 1,301 1,290 1,290 1,289 2,351
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest
-2.39 -0.20 0.33 1.40 0.53 -0.22 0.65 -0.23
Total Equity & Noncontrolling Interests
-1,128 -1,213 -1,350 -1,195 -1,037 -1,082 -1,219 -1,638
Total Preferred & Common Equity
-1,138 -1,226 -1,362 -1,208 -1,050 -1,093 -1,230 -1,648
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
-1,138 -1,226 -1,362 -1,208 -1,050 -1,093 -1,230 -1,648
Common Stock
917 1,107 1,128 1,460 1,821 1,851 1,876 1,939
Retained Earnings
-1,781 -2,057 -2,215 -2,392 -2,596 -2,669 -2,831 -3,264
Treasury Stock
-275 -275 -275 -275 -275 -275 -275 -323
Accumulated Other Comprehensive Income / (Loss)
-0.35 -0.01 0.06 0.03 0.00 -0.00 0.01 0.00
Noncontrolling Interest
10 12 12 12 12 11 11 9.96

Annual Metrics and Ratios for BridgeBio Pharma

This table displays calculated financial ratios and metrics derived from BridgeBio Pharma's official financial filings.

Metric 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics
- - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% -79.66% 745.14% 11.38% -88.02% 2,285.27%
EBITDA Growth
0.00% -328.56% -42.06% -76.55% -13.49% 24.30% -44.08% 1.52%
EBIT Growth
0.00% -328.56% -42.51% -76.52% -14.37% 23.86% -43.29% 1.58%
NOPAT Growth
0.00% -318.76% -44.96% -78.22% -21.53% 11.17% -18.58% 2.37%
Net Income Growth
0.00% -286.59% -70.31% -75.16% -16.02% 17.36% -34.79% 16.82%
EPS Growth
0.00% -112.00% -16.98% -53.23% -2.63% 16.41% -21.17% 27.09%
Operating Cash Flow Growth
0.00% -237.49% -85.58% -57.62% -24.57% 15.75% -25.80% 1.33%
Free Cash Flow Firm Growth
0.00% 0.00% -84.78% 132.19% 625.00% -166.23% -30.97% 120.57%
Invested Capital Growth
0.00% 0.00% 55.94% -4,225.81% -213.74% -4.10% -1.80% -36.93%
Revenue Q/Q Growth
0.00% 0.00% 0.00% -62.41% 22.41% -12.42% -1.33% 1.90%
EBITDA Q/Q Growth
0.00% 0.00% 0.00% -10.36% -2.24% 3.06% -5.62% -13.64%
EBIT Q/Q Growth
0.00% 0.00% 0.00% -10.70% -2.43% 2.98% -5.54% -13.43%
NOPAT Q/Q Growth
0.00% 0.00% 0.00% -11.48% -7.08% 6.63% -8.62% -8.93%
Net Income Q/Q Growth
0.00% 0.00% 0.00% -11.19% -3.03% 2.36% -4.77% -21.75%
EPS Q/Q Growth
0.00% 0.00% 0.00% -12.09% 0.26% 2.69% -1.54% -19.01%
Operating Cash Flow Q/Q Growth
0.00% 0.00% -13.31% -5.28% -8.18% 8.83% -6.36% -15.66%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00% 0.00% -2.43% 80.97% -144.75% 123.95%
Invested Capital Q/Q Growth
0.00% 0.00% 0.00% -1.61% -1.73% -5,495.73% -2.72% -36.85%
Profitability Metrics
- - - - - - - -
Gross Margin
0.00% 0.00% 100.00% 100.00% 95.53% 95.58% 73.71% 98.25%
EBITDA Margin
0.00% 0.00% -658.30% -5,714.54% -767.35% -521.57% -6,272.23% -258.95%
Operating Margin
0.00% 0.00% -656.41% -5,751.99% -827.12% -659.65% -6,528.75% -267.22%
EBIT Margin
0.00% 0.00% -660.42% -5,732.19% -775.73% -530.29% -6,342.04% -261.69%
Profit (Net Income) Margin
0.00% 0.00% -711.50% -6,127.87% -841.20% -624.17% -7,021.94% -244.86%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.21%
Interest Burden Percent
99.94% 90.15% 107.73% 106.90% 108.44% 117.70% 110.72% 93.37%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
0.00% -44.90% -67.64% -173.15% 154.80% 45.93% 50.49% 38.81%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% -48.85% -70.82% -63.02% -50.34% -100.91% -79.24%
Return on Assets (ROA)
0.00% 0.00% -52.63% -75.71% -68.34% -59.25% -111.72% -74.14%
Return on Common Equity (ROCE)
0.00% -37.47% -57.33% -138.31% 166.00% 46.24% 50.91% 39.11%
Return on Equity Simple (ROE_SIMPLE)
0.00% -53.81% -70.65% -872.95% 67.38% 38.63% 48.24% 37.02%
Net Operating Profit after Tax (NOPAT)
-31 -129 -186 -332 -404 -359 -425 -415
NOPAT Margin
0.00% 0.00% -459.49% -4,026.40% -578.98% -461.75% -4,570.13% -187.06%
Net Nonoperating Expense Percent (NNEP)
0.00% -20.51% -23.13% -34.72% -39.77% -52.01% -543.39% -65.32%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - 44.14% 47.42% 40.68%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 4.47% 4.42% 26.29% 1.75%
SG&A Expenses to Revenue
0.00% 0.00% 232.63% 1,766.08% 275.70% 184.41% 1,618.73% 130.21%
R&D to Revenue
0.00% 0.00% 517.62% 4,085.91% 646.94% 514.45% 4,898.54% 228.24%
Operating Expenses to Revenue
0.00% 0.00% 756.41% 5,851.99% 922.65% 755.22% 6,602.46% 365.48%
Earnings before Interest and Taxes (EBIT)
-44 -188 -268 -473 -541 -412 -590 -581
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-44 -188 -267 -471 -535 -405 -584 -575
Valuation Ratios
- - - - - - - -
Price to Book Value (P/BV)
0.00 1.11 10.60 150.52 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)
0.00 1.11 10.60 150.52 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
0.00 0.00 106.79 1,056.59 35.21 14.67 754.92 23.37
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 96.49 1,000.44 29.46 13.78 755.64 21.67
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 129.31 4.44 0.00 0.00 58.26
Leverage & Solvency
- - - - - - - -
Debt to Equity
0.00 0.14 0.19 0.87 -0.50 -0.35 -0.33 -0.30
Long-Term Debt to Equity
0.00 0.14 0.19 0.86 -0.50 -0.35 -0.33 -0.30
Financial Leverage
0.00 -1.06 -1.04 -1.71 1.21 0.23 0.03 0.14
Leverage Ratio
0.00 1.23 1.29 2.29 -2.27 -0.78 -0.45 -0.52
Compound Leverage Factor
0.00 1.11 1.38 2.44 -2.46 -0.91 -0.50 -0.49
Debt to Total Capital
0.00% 12.62% 16.17% 46.53% -99.06% -52.95% -49.82% -42.86%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.72% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 12.62% 16.17% 45.81% -99.06% -52.95% -49.82% -42.86%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 14.47% 11.89% 24.77% -1.11% -1.19% -1.31% -1.01%
Common Equity to Total Capital
0.00% 72.91% 71.94% 28.70% 200.17% 154.14% 151.13% 143.87%
Debt to EBITDA
0.00 -0.29 -0.34 -0.20 -0.81 -1.06 -0.77 -0.76
Net Debt to EBITDA
0.00 2.12 1.82 1.09 0.76 0.19 0.01 0.67
Long-Term Debt to EBITDA
0.00 -0.29 -0.34 -0.20 -0.81 -1.06 -0.77 -0.76
Debt to NOPAT
0.00 -0.42 -0.49 -0.28 -1.07 -1.20 -1.05 -1.05
Net Debt to NOPAT
0.00 3.10 2.60 1.55 1.01 0.22 0.01 0.93
Long-Term Debt to NOPAT
0.00 -0.42 -0.49 -0.28 -1.07 -1.20 -1.05 -1.05
Altman Z-Score
0.00 1.58 15.35 5.74 -2.00 -5.18 -7.14 -4.51
Noncontrolling Interest Sharing Ratio
0.00% 16.56% 15.23% 20.13% -7.23% -0.69% -0.83% -0.79%
Liquidity Ratios
- - - - - - - -
Current Ratio
0.00 13.67 9.42 6.72 6.58 4.52 3.32 4.67
Quick Ratio
0.00 13.39 9.09 6.35 6.34 4.03 3.04 4.44
Cash Flow Metrics
- - - - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -107 -198 64 463 -306 -401 83
Operating Cash Flow to CapEx
-8,725.86% -6,273.78% -9,612.85% -5,316.76% -3,759.13% 0.00% -40,407.35% -55,812.00%
Free Cash Flow to Firm to Interest Expense
0.00 -42.13 -22.62 1.74 9.89 -3.81 -4.94 0.66
Operating Cash Flow to Interest Expense
-3,114.46 -53.65 -28.93 -10.90 -10.64 -5.22 -6.49 -4.14
Operating Cash Flow Less CapEx to Interest Expense
-3,150.15 -54.50 -29.23 -11.11 -10.93 -5.15 -6.51 -4.14
Efficiency Ratios
- - - - - - - -
Asset Turnover
0.00 0.00 0.07 0.01 0.08 0.09 0.02 0.30
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 68.56
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 11.27 0.64 2.77 3.48 0.71 23.57
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.30 0.29 0.22 0.38
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 5.32
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 1,220.71 1,245.83 1,657.35 954.05
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 -1,220.71 -1,245.83 -1,657.35 -948.73
Capital & Investment Metrics
- - - - - - - -
Invested Capital
0.00 -21 -9.37 -405 -1,272 -1,324 -1,348 -1,845
Invested Capital Turnover
0.00 0.00 -2.65 -0.04 -0.08 -0.06 -0.01 -0.14
Increase / (Decrease) in Invested Capital
0.00 -21 12 -396 -866 -52 -24 -498
Enterprise Value (EV)
0.00 12 3,913 8,253 2,053 1,070 7,030 4,809
Market Capitalization
349 349 4,331 8,716 2,455 1,139 7,023 5,186
Book Value per Share
$0.00 $5.10 $3.31 $0.47 ($5.91) ($8.39) ($7.78) ($7.77)
Tangible Book Value per Share
$0.00 $5.10 $3.31 $0.47 ($6.22) ($8.59) ($7.94) ($7.89)
Total Capital
0.00 432 568 202 -435 -814 -896 -1,020
Total Debt
0.00 55 92 94 431 431 446 437
Total Long-Term Debt
0.00 55 92 92 431 431 446 437
Net Debt
0.00 -399 -485 -513 -406 -79 -5.09 -388
Capital Expenditures (CapEx)
0.46 2.18 2.64 7.52 13 -5.18 1.31 0.93
Debt-free, Cash-free Net Working Capital (DFCFNWC)
0.00 -23 -38 -58 -83 -82 -118 -115
Debt-free Net Working Capital (DFNWC)
0.00 413 508 549 754 427 334 566
Net Working Capital (NWC)
0.00 413 508 547 754 427 334 566
Net Nonoperating Expense (NNE)
13 41 102 173 183 126 228 128
Net Nonoperating Obligations (NNO)
0.00 -399 -485 -513 -406 -79 -5.09 -388
Total Depreciation and Amortization (D&A)
0.00 0.00 0.86 1.46 5.84 6.77 6.49 6.08
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% -93.09% -708.68% -119.13% -106.15% -1,266.13% -51.80%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 1,253.05% 6,650.92% 1,081.23% 550.46% 3,587.54% 255.20%
Net Working Capital to Revenue
0.00% 0.00% 1,253.05% 6,633.24% 1,081.23% 550.46% 3,587.54% 255.20%
Earnings Adjustments
- - - - - - - -
Adjusted Basic Earnings per Share
$0.00 $0.00 ($2.48) ($3.80) ($3.90) ($3.26) ($3.95) ($2.88)
Adjusted Weighted Average Basic Shares Outstanding
0.00 0.00 123.77M 148.96M 147.61M 147.47M 162.79M 186.08M
Adjusted Diluted Earnings per Share
$0.00 $0.00 ($2.48) ($3.80) ($3.90) ($3.26) ($3.95) ($2.88)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 0.00 123.77M 148.96M 147.61M 147.47M 162.79M 186.08M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 ($2.48) ($3.80) ($3.90) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 0.00 105.10M 118.00M 144.36M 151.37M 175.83M 190.19M
Normalized Net Operating Profit after Tax (NOPAT)
-31 -129 -186 -332 -404 -328 -420 -404
Normalized NOPAT Margin
0.00% 0.00% -459.49% -4,026.40% -578.98% -422.30% -4,510.49% -182.13%
Pre Tax Income Margin
0.00% 0.00% -711.50% -6,127.87% -841.20% -624.17% -7,021.94% -244.34%
Debt Service Ratios
- - - - - - - -
EBIT to Interest Expense
-3,373.69 -73.80 -30.56 -12.90 -11.56 -5.12 -7.26 -4.61
NOPAT to Interest Expense
-2,361.58 -50.48 -21.26 -9.06 -8.63 -4.46 -5.23 -3.30
EBIT Less CapEx to Interest Expense
-3,409.38 -74.65 -30.86 -13.11 -11.84 -5.05 -7.27 -4.62
NOPAT Less CapEx to Interest Expense
-2,397.28 -51.33 -21.56 -9.27 -8.91 -4.39 -5.25 -3.30
Payout Ratios
- - - - - - - -
Dividend Payout Ratio
-2.63% -26.10% -19.06% -0.99% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
-2.63% -26.10% -19.06% -15.83% -34.10% 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for BridgeBio Pharma

This table displays calculated financial ratios and metrics derived from BridgeBio Pharma's official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Growth Metrics
- - - - - - - - - - -
Revenue Growth
-85.58% -85.49% 7.79% -97.77% 1,110.36% -6.68% 11,461.88% 32.11% -33.22% 237.08% -44.76%
EBITDA Growth
19.20% 9.42% 30.24% -871.40% -33.18% -25.23% 109.13% -22.11% -16.78% -44.78% -930.48%
EBIT Growth
18.24% 9.22% 30.06% -953.03% -32.73% -24.84% 107.75% -21.81% -16.55% -44.18% -1,078.43%
NOPAT Growth
13.63% 21.97% 27.36% -82.22% -22.13% -37.28% 100.27% -20.15% -21.60% -27.40% -30,529.15%
Net Income Growth
12.93% 7.69% 29.11% -6,179.91% -28.03% -21.17% 74.67% 52.99% 8.49% -56.98% -369.05%
EPS Growth
12.26% 9.00% 31.85% -1,300.00% -16.13% -6.59% 78.26% 60.20% 20.37% -47.42% -340.00%
Operating Cash Flow Growth
-11.19% 30.36% 10.16% -272.22% -7.45% -33.86% -52.12% 165.90% -24.33% -56.49% 9.25%
Free Cash Flow Firm Growth
-276.39% -105.11% 48.50% 190.93% 189.45% -161.69% -141.29% -107.24% -108.30% 438.23% 745.11%
Invested Capital Growth
98.11% -4.10% -1.32% -3,397.34% -5,445.64% -1.80% 13.34% -2.89% -2.78% -36.93% -105.66%
Revenue Q/Q Growth
-99.54% 453.25% -2.35% -10.13% 149.30% -57.35% 11,998.57% -98.97% 26.01% 115.30% 1,882.88%
EBITDA Q/Q Growth
-753.54% -1.55% -1.72% -14.27% -12.83% 4.51% 107.41% -1,628.60% -7.91% -18.37% 57.47%
EBIT Q/Q Growth
-824.22% -1.54% -1.68% -14.09% -12.69% 4.50% 106.31% -1,892.91% -7.82% -18.14% 57.16%
NOPAT Q/Q Growth
-61.04% -0.09% 2.37% -15.80% -7.94% -12.51% 100.19% -51,277.55% -9.24% -17.88% 53.82%
Net Income Q/Q Growth
-5,378.43% -0.27% -1.54% -12.59% -11.69% 5.10% 78.77% -108.92% -117.43% -62.79% 36.57%
EPS Q/Q Growth
-1,228.57% 2.15% -1.10% -6.52% -10.20% 10.19% 79.38% -95.00% -120.51% -66.28% 38.46%
Operating Cash Flow Q/Q Growth
-343.84% 31.01% -54.78% 21.46% -28.12% 14.05% -75.88% 134.03% -341.71% -8.17% -2.00%
Free Cash Flow Firm Q/Q Growth
-2.07% 97.09% -86.38% 1,741.37% 0.41% -108.52% -71.85% 50.76% -15.19% 447.01% 227.76%
Invested Capital Q/Q Growth
36.98% -5,495.73% 2.20% -1.41% 0.07% -2.72% 16.75% -20.40% 0.18% -36.85% -25.05%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
-118.64% -6.68% 64.35% 63.50% 85.38% 65.73% 99.72% 72.42% 78.11% 64.57% 97.74%
EBITDA Margin
-35,840.24% -6,578.18% -6,852.74% -8,713.35% -3,943.68% -8,828.25% 5.41% -8,053.37% -6,896.60% -3,791.84% -81.33%
Operating Margin
-38,200.00% -6,910.80% -6,909.26% -8,903.05% -3,854.61% -10,167.11% 0.16% -8,096.82% -7,018.67% -3,842.69% -89.49%
EBIT Margin
-36,326.92% -6,666.95% -6,942.17% -8,813.10% -3,983.74% -8,919.08% 4.65% -8,125.97% -6,952.89% -3,815.08% -82.43%
Profit (Net Income) Margin
-41,477.22% -7,517.11% -7,816.65% -9,792.99% -4,387.39% -9,760.92% -17.13% -3,484.50% -6,012.23% -4,545.89% -145.42%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.43% 100.00%
Interest Burden Percent
114.18% 112.75% 112.60% 111.12% 110.13% 109.44% -368.00% 42.88% 86.47% 118.64% 176.42%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
53.19% 45.93% 37.80% 49.41% 53.65% 50.49% 48.58% 37.96% 37.00% 38.81% 50.59%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
-4,265.33% -632.92% -750.56% -73.23% -54.29% -141.91% 1.38% -2,743.52% -2,294.11% -1,155.17% -12.14%
Return on Assets (ROA)
-4,870.06% -713.63% -845.10% -81.38% -59.79% -155.30% -5.08% -1,176.45% -1,983.74% -1,376.45% -21.41%
Return on Common Equity (ROCE)
53.64% 46.24% 38.01% 49.89% 54.16% 50.91% 49.12% 38.32% 37.39% 39.11% 51.02%
Return on Equity Simple (ROE_SIMPLE)
43.60% 0.00% 34.76% 42.89% 51.63% 0.00% 52.09% 42.23% 36.29% 0.00% 41.06%
Net Operating Profit after Tax (NOPAT)
-90 -90 -88 -102 -110 -124 0.24 -123 -134 -158 -73
NOPAT Margin
-26,740.00% -4,837.56% -4,836.48% -6,232.13% -2,698.23% -7,116.97% 0.11% -5,667.77% -4,913.07% -2,689.88% -62.64%
Net Nonoperating Expense Percent (NNEP)
16.81% -20.67% -34.21% 11.52% 13.98% -109.91% -43.82% 40.81% -24.20% -55.60% -25.61%
Return On Investment Capital (ROIC_SIMPLE)
- 11.14% - - - 13.85% - - - 15.51% 4.46%
Cost of Revenue to Revenue
218.64% 106.68% 35.65% 36.50% 14.62% 34.27% 0.28% 27.58% 21.89% 35.43% 2.26%
SG&A Expenses to Revenue
9,227.22% 1,703.85% 1,703.61% 2,201.22% 874.53% 2,726.82% 31.17% 2,745.53% 2,519.00% 1,611.39% 91.20%
R&D to Revenue
27,370.12% 4,861.07% 5,085.49% 6,550.15% 3,058.81% 7,462.81% 66.77% 5,290.36% 4,408.64% 2,216.08% 95.54%
Operating Expenses to Revenue
38,081.36% 6,976.20% 6,973.60% 8,966.54% 3,939.99% 10,232.84% 99.55% 8,169.23% 7,096.78% 3,907.26% 187.22%
Earnings before Interest and Taxes (EBIT)
-123 -125 -127 -145 -163 -156 9.83 -176 -190 -224 -96
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-121 -123 -125 -143 -161 -154 11 -175 -188 -223 -95
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
16.62 14.67 32.27 486.45 454.43 754.92 24.61 21.63 21.98 23.37 51.60
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
29.19 13.78 31.38 495.11 443.36 755.64 24.28 20.45 21.44 21.67 46.43
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 3.11 4.66 0.00 0.00 0.00 0.00 58.26 8.49
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
-1.50 -0.35 -0.36 -0.33 -0.37 -0.33 -0.42 -0.40 -0.36 -0.30 0.00
Long-Term Debt to Equity
-1.50 -0.35 -0.36 -0.33 -0.37 -0.33 -0.42 -0.40 -0.36 -0.30 0.00
Financial Leverage
-0.32 0.23 0.14 -0.43 -0.43 0.03 0.07 0.10 0.10 0.14 0.28
Leverage Ratio
-0.81 -0.78 -0.64 -0.58 -0.60 -0.45 -0.66 -0.53 -0.55 -0.52 -0.65
Compound Leverage Factor
-0.92 -0.87 -0.72 -0.64 -0.66 -0.49 2.41 -0.23 -0.47 -0.62 -1.14
Debt to Total Capital
298.90% -52.95% -56.02% -48.45% -58.74% -49.82% -72.20% -67.34% -55.77% -42.86% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
298.90% -52.95% -56.02% -48.45% -58.74% -49.82% -72.20% -67.34% -55.77% -42.86% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
1.42% -1.19% -1.55% -1.36% -1.84% -1.31% -2.10% -1.68% -1.47% -1.01% -0.59%
Common Equity to Total Capital
-200.31% 154.14% 157.57% 149.81% 160.57% 151.13% 174.30% 169.01% 157.24% 143.87% 100.59%
Debt to EBITDA
-4.07 -1.06 -1.24 -0.86 -0.80 -0.77 -0.97 -0.91 -0.86 -0.76 0.00
Net Debt to EBITDA
-2.65 0.19 0.23 -0.07 0.21 0.01 0.19 0.56 0.26 0.67 0.00
Long-Term Debt to EBITDA
-4.07 -1.06 -1.24 -0.86 -0.80 -0.77 -0.97 -0.91 -0.86 -0.76 0.00
Debt to NOPAT
-4.42 -1.20 -1.34 -1.19 -1.13 -1.05 -1.29 -1.22 -1.14 -1.05 0.00
Net Debt to NOPAT
-2.88 0.22 0.25 -0.10 0.30 0.01 0.25 0.75 0.34 0.93 0.00
Long-Term Debt to NOPAT
-4.42 -1.20 -1.34 -1.19 -1.13 -1.05 -1.29 -1.22 -1.14 -1.05 0.00
Altman Z-Score
-2.52 -3.66 -3.45 -5.43 -3.65 -4.52 -1.37 -2.92 -4.50 -3.23 -3.09
Noncontrolling Interest Sharing Ratio
-0.83% -0.69% -0.55% -0.97% -0.94% -0.83% -1.10% -0.95% -1.05% -0.79% -0.84%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
5.39 4.52 5.72 3.93 5.54 3.32 5.54 4.59 3.19 4.67 4.57
Quick Ratio
5.17 4.03 5.20 3.56 5.17 3.04 5.34 3.34 1.92 4.44 4.31
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-1,317 -38 -71 1,173 1,178 -100 -172 -85 -98 339 1,112
Operating Cash Flow to CapEx
-17,808.04% -11,640.82% -1,202,683.33% -26,484.35% -33,695.13% -28,694.02% -31,588.06% 138,338.89% -131,800.00% -415,587.23% 0.00%
Free Cash Flow to Firm to Interest Expense
-66.42 -1.92 -3.55 56.96 58.01 -4.95 -3.44 -3.70 -4.24 11.38 17.58
Operating Cash Flow to Interest Expense
-6.82 -4.66 -7.17 -5.50 -7.15 -6.16 -4.39 3.26 -7.83 -6.55 -3.15
Operating Cash Flow Less CapEx to Interest Expense
-6.86 -4.70 -7.17 -5.53 -7.17 -6.18 -4.40 3.25 -7.84 -6.55 -3.15
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.12 0.09 0.11 0.01 0.01 0.02 0.30 0.34 0.33 0.30 0.15
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 68.56 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
4.09 3.48 5.06 0.38 0.67 0.71 17.50 19.15 20.63 23.57 14.07
Accounts Payable Turnover
0.41 0.29 0.58 0.63 0.53 0.22 0.54 0.22 0.27 0.38 0.37
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5.32 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
889.57 1,245.83 633.63 580.25 694.76 1,657.35 671.43 1,678.51 1,360.74 954.05 994.45
Cash Conversion Cycle (CCC)
-889.57 -1,245.83 -633.63 -580.25 -694.76 -1,657.35 -671.43 -1,678.51 -1,360.74 -948.73 -994.45
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-24 -1,324 -1,295 -1,313 -1,312 -1,348 -1,122 -1,351 -1,348 -1,845 -2,307
Invested Capital Turnover
-0.14 -0.06 -0.06 -0.01 -0.01 -0.01 -0.18 -0.16 -0.16 -0.14 -0.07
Increase / (Decrease) in Invested Capital
1,226 -52 -17 -1,275 -1,288 -24 173 -38 -36 -498 -1,185
Enterprise Value (EV)
2,588 1,070 2,441 2,810 4,180 7,030 5,307 4,482 4,669 4,809 5,916
Market Capitalization
1,474 1,139 2,510 2,761 4,284 7,023 5,379 4,740 4,787 5,186 6,575
Book Value per Share
($7.68) ($8.39) ($8.10) ($8.49) ($7.43) ($7.78) ($5.87) ($5.84) ($6.54) ($7.77) ($8.67)
Tangible Book Value per Share
($7.88) ($8.59) ($8.28) ($8.66) ($7.60) ($7.94) ($6.02) ($5.97) ($6.67) ($7.89) ($8.81)
Total Capital
568 -814 -778 -909 -752 -896 -602 -647 -782 -1,020 -1,639
Total Debt
1,699 431 436 440 442 446 435 435 436 437 0.00
Total Long-Term Debt
1,699 431 436 440 442 446 435 435 436 437 0.00
Net Debt
1,107 -79 -81 37 -118 -5.09 -85 -269 -130 -388 -669
Capital Expenditures (CapEx)
0.76 0.80 0.01 0.43 0.43 0.44 0.70 0.05 0.14 0.05 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-69 -82 -61 -81 -78 -118 122 -105 -100 -115 2.47
Debt-free Net Working Capital (DFNWC)
523 427 456 323 482 334 642 482 305 566 543
Net Working Capital (NWC)
523 427 456 323 482 334 642 482 305 566 543
Net Nonoperating Expense (NNE)
50 50 54 58 69 46 36 -47 30 109 97
Net Nonoperating Obligations (NNO)
1,107 -79 -81 37 -118 -5.09 -85 -269 -130 -388 -669
Total Depreciation and Amortization (D&A)
1.65 1.66 1.63 1.64 1.64 1.59 1.60 1.57 1.54 1.37 1.28
Debt-free, Cash-free Net Working Capital to Revenue
-77.77% -106.15% -78.03% -1,426.61% -830.63% -1,266.13% 55.87% -48.06% -46.09% -51.80% 1.94%
Debt-free Net Working Capital to Revenue
589.90% 550.46% 586.41% 5,687.47% 5,108.24% 3,587.54% 293.67% 219.91% 140.23% 255.20% 426.22%
Net Working Capital to Revenue
589.90% 550.46% 586.41% 5,687.47% 5,108.24% 3,587.54% 293.67% 219.91% 140.23% 255.20% 426.22%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.93) ($0.91) ($0.92) ($0.98) ($1.08) ($0.97) ($0.20) ($0.39) ($0.86) ($1.43) ($0.88)
Adjusted Weighted Average Basic Shares Outstanding
147.94M 147.47M 152.65M 160.54M 163.31M 162.79M 178.71M 187.59M 188.51M 186.08M 190.15M
Adjusted Diluted Earnings per Share
($0.93) ($0.91) ($0.92) ($0.98) ($1.08) ($0.97) ($0.20) ($0.39) ($0.86) ($1.43) ($0.88)
Adjusted Weighted Average Diluted Shares Outstanding
147.94M 147.47M 152.65M 160.54M 163.31M 162.79M 178.71M 187.59M 188.51M 186.08M 190.15M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
149.48M 151.37M 160.50M 162.47M 173.97M 175.83M 187.13M 188.03M 188.99M 190.19M 189.88M
Normalized Net Operating Profit after Tax (NOPAT)
-87 -85 -86 -100 -110 -124 2.62 -121 -131 -155 -73
Normalized NOPAT Margin
-25,701.18% -4,549.66% -4,707.33% -6,081.51% -2,693.57% -7,086.73% 1.24% -5,574.43% -4,794.67% -2,634.03% -62.30%
Pre Tax Income Margin
-41,477.22% -7,517.11% -7,816.65% -9,792.99% -4,387.39% -9,760.92% -17.13% -3,484.50% -6,012.23% -4,526.28% -145.42%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-6.19 -6.24 -6.30 -7.02 -8.03 -7.68 0.20 -7.68 -8.24 -7.53 -1.52
NOPAT to Interest Expense
-4.56 -4.53 -4.39 -4.97 -5.44 -6.13 0.00 -5.36 -5.82 -5.31 -1.15
EBIT Less CapEx to Interest Expense
-6.23 -6.28 -6.30 -7.04 -8.05 -7.70 0.18 -7.68 -8.24 -7.53 -1.52
NOPAT Less CapEx to Interest Expense
-4.60 -4.57 -4.39 -4.99 -5.46 -6.15 -0.01 -5.36 -5.83 -5.31 -1.15
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About BridgeBio Pharma's Financials

When does BridgeBio Pharma's financial year end?

According to the most recent income statement we have on file, BridgeBio Pharma's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has BridgeBio Pharma's net income changed over the last 7 years?

BridgeBio Pharma's net income appears to be on an upward trend, with a most recent value of -$543.35 million in 2024, rising from -$43.83 million in 2017. The previous period was -$653.25 million in 2023. See where experts think BridgeBio Pharma is headed by visiting BridgeBio Pharma's forecast page.

What is BridgeBio Pharma's operating income?
BridgeBio Pharma's total operating income in 2024 was -$592.97 million, based on the following breakdown:
  • Total Gross Profit: $218.02 million
  • Total Operating Expenses: $811.00 million
How has BridgeBio Pharma revenue changed over the last 7 years?

Over the last 7 years, BridgeBio Pharma's total revenue changed from $0.00 in 2017 to $221.90 million in 2024, a change of 22,190,200,000.0%.

How much debt does BridgeBio Pharma have?

BridgeBio Pharma's total liabilities were at $2.38 billion at the end of 2024, a 25.8% increase from 2023, and a 2,614.1% increase since 2018.

How much cash does BridgeBio Pharma have?

In the past 6 years, BridgeBio Pharma's cash and equivalents has ranged from $356.08 million in 2020 to $681.10 million in 2024, and is currently $681.10 million as of their latest financial filing in 2024.

How has BridgeBio Pharma's book value per share changed over the last 7 years?

Over the last 7 years, BridgeBio Pharma's book value per share changed from 0.00 in 2017 to -7.77 in 2024, a change of -776.7%.



This page (NASDAQ:BBIO) was last updated on 5/5/2025 by MarketBeat.com Staff
From Our Partners